A Type 2 diabetes medication called lixisenatide appeared to slow the progression of Parkinson’s disease symptoms in a small, mid-stage trial funded by the French Ministry of Health and others ...

Soliqua 100/33 (insulin glargine/lixisenatide) is a prescription drug that’s used to treat type 2 diabetes. Soliqua 100/33 comes as a prefilled single-use pen for injecting the drug under your skin.

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

Sanofi has finally had is type 2 diabetes drug, lixisenatide, approved in the US, creating further competition against Novo Nordisk’s market leading Victoza. The French pharma withdrew its US ...